Antitumor effectiveness of a combined therapy with a new cucurbitacin B derivative and paclitaxel on a human lung cancer xenograft model

Toxicology and Applied Pharmacology

Volumn 329, Issue , 2017, Pages 272-281

  Marostica, Lucas Lourenço ^a   de Barros, André Luís Branco ^b   Oliveira, Juliana ^b   Salgado, Breno Souza ^c   Cassali, Geovanni Dantas ^b   Leite, Elaine Amaral ^b   Cardoso, Valbert Nascimento ^b   Lang, Karen Luise ^a   Caro, Miguel Soriano Balparda ^a   Durán, Fernando Javier ^d   Schenkel, Eloir Paulo ^a   de Oliveira, Mônica Cristina ^b   Simões, Cláudia Maria Oliveira ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Antitumor effect; Cucurbitacins; Lung cancer; Paclitaxel; Scintigraphic images; Xenograft lung tumor

Indexed keywords

2 DEOXY 2 AMINE CUCURBITACIN E; CUCURBITACIN; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CUCURBITACIN B; KI 67 ANTIGEN; RADIOPHARMACEUTICAL AGENT; TRITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER INHIBITION; CANCER SIZE; CHRONIC TOXICITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; REVIEW; SCINTIGRAPHY; TUMOR XENOGRAFT; A-549 CELL LINE; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DIAGNOSTIC IMAGING; DRUG EFFECTS; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; TIME FACTOR; TOXICITY TESTING; TUMOR VOLUME; WHOLE BODY IMAGING;

A549 CELLS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; FEMALE; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MICE, INBRED BALB C; MICE, NUDE; PACLITAXEL; RADIOPHARMACEUTICALS; TIME FACTORS; TOXICITY TESTS, SUBCHRONIC; TRITERPENES; TUMOR BURDEN; WHOLE BODY IMAGING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85020883460     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2017.06.007     Document Type: Review

References (45)

1. Abdallah, H.M., Al-Abd, A.M., El-Dine, R.S., El-Halawani, A.M., P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review. J. Adv. Res. 6 (2015), 45–62.
2. Alghasham, A.A., Cucurbitacins – a promising target for cancer therapy. Int. J. Health Sci. 7 (2013), 77–89.
3. Ansari, J., Shackelford, R.E., El-Osta, H., Epigenetics in non-small cell lung cancer: from basics to therapeutics. Transl. Lung Cancer Res. 5 (2016), 155–171.
4. Aribi, A., Gery, S., Lee, D.H., Thoennissen, N.H., Thoennissen, G.B., Alvarez, R., Ho, Q., Lee, K., Doan, N.B., Chan, K.T., Toh, M., Said, J.W., Koeffler, H.P., The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer. Int. J. Cancer 132 (2013), 2730–2737.
5. Arumuggam, N., Bhowmick, N.A., Rupasinghe, H.V.P., A review: phytochemicals targeting JAK/STAT signaling and IDO expression in cancer. Phytother. Res. 29 (2015), 805–817.
6. Cai, Y., Fang, X., He, C., Li, P., Xiao, F., Wang, Y., Chen, M., Cucurbitacins: a systematic review of the phytochemistry and anticancer activity. Am. J. Chin. Med. 43 (2015), 1331–1350.
7. Callaghan, R., Luk, F., Bebawy, M., Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?. Drug Metab. Dispos. 42 (2014), 623–631.
8. Chen, J.C., Chiu, M.H., Nie, R.L., Cordell, G.A., Qiu, S.X., Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat. Prod. Rep. 22 (2005), 386–399.
9. Chen, X., Bao, J., Guo, J., Ding, Q., Lu, J., Huang, M., Wang, Y., Biological activities and potential molecular targets of cucurbitacins: a focus on cancer. Anti-Cancer Drugs 23 (2012), 777–787.
10. Chen, Z., Fillmore, C.M., Hammerman, P.S., Kim, C.F., Wong, K.-K., Non-small cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer 14 (2014), 535–546.
11. Chou, T.C., Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58 (2006), 621–681.
12. Custodio, A., Méndez, M., Provencio, M., Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat. Rev. 38 (2012), 36–53.
13. De Barros, A.L.B., Mota, L.G., Soares, D.C.F., Coelho, M.M.A., Oliveira, M.C., Cardoso, V.N., Tumor bombesin analog loaded long-circulating and pH-sensitive liposomes as tool for tumor identification. Bioorg. Med. Chem. Lett. 21 (2011), 7373–7375.
14. 99mTc-labeled bombesin analog for breast cancer identification. J. Radioanal. Nucl. Chem. 295 (2013), 2083–2090.
15. Devarakonda, S., Morgensztern, D., Govindan, R., Genomic alterations in lung adenocarcinoma. Lancet Oncol. 16 (2015), 342–351.
16. Diniz, S.O., Rezende, S.M., Serakides, R., Ferreira, R.L., Ribeiro, T.G., Martin-Comin, J., Cardoso, V.N., Scintigraphic imaging using technetium-99m-labeled ceftizoxime in an experimental model of acute osteomyelitis in rats. Nucl. Med. Commun. 29 (2008), 830–836.
17. Huang, G.S., Lopez-Barcons, L., Freeze, B.S., Smith, A.B., Goldberg, G.L., Horwitz, S.B., McDaid, H.M., Potentiation of taxol efficacy by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin. Cancer Res. 12 (2006), 298–304.
18. Iwanski, G.B., Lee, D.H., En-gal, S., Doan, N.B., Castor, B., Vogt, M., Toh, M., Bokemeyer, C., Said, J.W., Thoennissen, N.H., Koeffler, H.P., Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br. J. Pharmacol. 160 (2010), 998–1007.
19. Jang, S.H., Wientjes, M.G., Au, J.L., Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J. Pharmacol. Exp. Ther. 298 (2001), 1236–1242.
20. Jarrar, B.M., Taib, N.T., Histological and histochemical alterations in the liver induced by lead chronic toxicity. Saudi J. Biol. Sci. 19 (2012), 203–210.
21. Kausar, H., Munagala, R., Bansal, S.S., Agil, F., Vadhanam, M.V., Gupta, R.C., Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets. Cancer Lett. 332 (2013), 35–45.
22. Kaushik, U., Aeri, V., Mir, S.R., Cucurbitacins – an insight into medicinal leads from nature. Pharmacogn. Rev. 9 (2015), 12–18.
23. Koh, P.K., Faivre-Finn, C., Blackhall, F.H., De Ruysscher, D., Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treat. Rev. 38 (2012), 626–640.
24. Kubota, K., From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann. Nucl. Med. 15 (2001), 471–486.
25. Lang, K.L., Guimarães, T., Machado, V.R., Zimmermann, L., Silva, I.T., Teixeira, M.R., Durán, F.J., Palermo, J.A., Simões, C.M.O., Caro, M.B.C., Schenkel, E.P., New cytotoxic cucurbutacins from Wilbrandia ebracteata Cogn. Planta Med. 77 (2011), 1648–1651.
26. Lang, K.L., Silva, I.T., Zimmermann, L., Machado, V.R., Teixeira, M.R., Lapuh, M.I., Galleti, M.A., Palermo, J.A., Cabrera, G.M., Bernardes, L.S.C., Simões, C.M.O., Schenkel, E.P., Caro, M.S.B., Durán, F.J., Synthesis and cytotoxic activity evaluation of dihydrocucurbitacin B and cucurbitacin B derivatives. Bioorg. Med. Chem. 20 (2012), 3016–3030.
27. Lang, K.L., Silva, I.T., Machado, V.R., Zimmermann, L., Caro, M.S.B., Simões, C.M.O., Schenkel, E.P., Durán, F.J., Bernardes, L.S.C., Melo, E.B., Multivariate SAR and QSAR of cucurbitacin derivatives as cytotoxic compounds in a human lung adenocarcinoma cell line. J. Mol. Graph. Model. 48 (2014), 70–79.
28. Lee, D.H., Iwanski, G.B., Thoennissen, N.H., Cucurbitacin: ancient compound shedding new light on cancer treatment. Sci. World J. 10 (2010), 413–418.
29. Li, F., Zhao, C., Wang, L., Molecular-targeted agents combination therapy for cancer: developments and potential. Int. J. Cancer 134 (2014), 1257–1269.
30. Liu, T., Peng, H., Zhang, M., Deng, Y., Wu, Z., Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin. Eur. J. Pharmacol. 641 (2010), 15–22.
31. Mandaliya, H., Baghi, P., Prawira, A., George, M.K., A rare case of paclitaxel and/or trastuzumab induced acute hepatic necrosis. Case Rep. Oncol. Med. 2015 (2015), 1–2.
32. Marostica, L.L., Silva, I.T., Kratz, J.M., Persich, L., Geller, F.C., Lang, K.L., Caro, M.S., Durán, F.J., Schenkel, E.P., Simões, C.M.O., Synergistic antiproliferative effects of a new cucurbitacin B derivative and chemotherapy drugs on lung cancer cell line A549. Chem. Res. Toxicol. 28 (2015), 1949–1960.
33. (7-14) as an agent to early visualization of lung tumor cells in nude mice. Nucl. Med. Commun. 37 (2016), 372–376.
34. Milanovic, D., Braun, F., Weber, W., Grosu, A.L., Behe, M., Niedermann, G., The influence of the combined treatment with vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts. BMC Cancer 12 (2012), 1–8.
35. Newman, D.J., Cragg, G.M., Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 79 (2016), 629–661.
36. Ramalhete, C., Molnár, J., Mulhovo, S., Rosário, V.E., Ferreira, M.J., New potent P-glycoprotein modulators with the cucurbitane scaffold and their synergistic interaction with doxorubicin on resistant cancer cells. Bioorg. Med. Chem. 17 (2009), 6942–6951.
37. Ríos, I., Andújar, J.M., Escandell, R.M., Recio, M.C., Cucurbitacins as inducers of cell death and a rich source of potential cancer compounds. Curr. Pharm. Design 18 (2012), 1663–1676.
38. Roland, C.L., Dineen, S.P., Lynn, K.D., Sullivan, L.A., Dellinger, M.T., Sadegh, L., Sullivan, J.P., Shames, D.S., Brekken, R.A., Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol. Cancer Ther. 8 (2009), 1761–1771.
39. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2017. CA Cancer J. Clin. 67 (2017), 7–30.
40. Silva, I.T., Teixeira, M.R., Lang, K., Guimarães, T.R., Dudek, S.E., Durán, F.J., Ludwig, S., Caro, M.S.B., Schenkel, E.P., Simões, C.M.O., Proliferative inhibition and apoptotic mechanism on human non-small-cell lung cancer (A549 cells) of a novel cucurbitacin from Wilbrandia ebracteata Cogn. Int. J. Cancer Res. 9 (2013), 54–68.
41. Silva, I.T., Carvalho, A., Lang, K.L., Dudek, S.E., Durán, F.J., Caro, M.S.B., Rapp, U.R., Wixler, V., Schenkel, E.P., Simões, C.M.O., Ludwig, S., In vitro and in vivo antitumor activity of a novel semisynthetic derivative of cucurbitacin B. PLoS One, 10(2), 2015, e0117794.
42. Sun, Y., Zhang, J., Zhou, J., Huang, Z., Hu, H., Qiao, M., Zhao, X., Chen, D., Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells. Eur. J. Pharmacol. 768 (2015), 28–40.
43. Wakimoto, N., Yin, D., O'Kelly, J., Haritunians, T., Karlan, B., Said, J., Xing, H., Koeffler, H.P., Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci. 99 (2008), 1793–1797.
44. Wall, M.E., Wani, M.C., Camptothecin and taxol: discovery to clinic – thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 55 (1995), 753–760.
45. Yamori, T., Sato, S., Chikasawa, H., Kadota, T., Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. J. Cancer Res. Ther. 88 (1997), 1205–1210.